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OBJECTIVES: To assess the characteristics of SLE patients currently experiencing 
flares in Europe. METHODS: A multi-center retrospective medical chart review 
of adult (16-89 yrs) SLE patients was conducted in 1Q2014 among rheumatolo-
gists/internal medicine physicians in UK/France/Germany/Italy/Spain (5EU). 
Physicians were recruited from a geographically representative sample in each 
country. Approx. 5 consecutive eligible persistent active or relapse remitting SLE 
patients currently managed as part of usual care were identified within the study 
observation window. Physicians abstracted de-identified patient data on disease 
characteristics, lab values and treatment patterns. Patient disease status and 
humanistic burden was assessed by physician per clinical judgment & patient 
interaction. Patients experiencing a flare were identified for analysis. RESULTS: 
135 SLE patients who were experiencing flares were included in the analysis 
(UK:45/France:22/Germany:20/Italy:20/Spain:28). Mean age(yrs) was 5EU:40.6/
UK:44.4/France:39.3/Germany:36.9/Italy:41.0/Spain:37.9; % female was 5EU:78%/
UK:87%/France:59%/Germany:75%/Italy:70%/Spain:86%; % full-time employment 
was 5EU:33%/UK:20%/France:32%/Germany:30%/Italy:50%/Spain:43%; % part-time 
employment was 5EU:18%/UK:29%/France:9%/Germany:10%/Italy:10%/Spain:18%; 
% on sick leave was 5EU:17%/UK:9%/France:23%/Germany:25%/Italy:15%/
Spain:21%. Top-5 organ manifestations observed were musculoskeletal (5EU:88%/
UK:93%/France:100%/Germany:65%/Italy:95%/Spain:82%), mucocutaneous 
(5EU:85%/UK:96%/France:91%/Germany:65%/Italy:80%/Spain:82%), haematologic 
(5EU:56%/UK:56%/France:41%/Germany:60%/Italy:50%/Spain:68%), renal (5EU:33%/
UK:33%/France:23%/Germany:50%/Italy:45%/Spain:21%) and pulmonary (5EU:27%/
UK:38%/France:5%/Germany:10%/Italy:35%/Spain:32%). Percentage of patients 
with low C3 (5EU:73%/UK:55%/France:62%/Germany:85%/Italy:90%/Spain:89%), 
low C4 (5EU:78%/UK:59%/France:90%/Germany:90%/Italy:75%/Spain:89%) and 
positive anti-ds-DNA (5EU:90%/UK:80%/France:100%/Germany:95%/Italy:95%/
Spain:93%) were high. Among those with lab measures, mean ESR (mm/h) was 
5EU:50.1/UK:44.4/France:47.6/Germany:41.2/Italy:54.6/Spain:63.8; mean hemo-
globin (g/L) was 5EU:10.4/UK:9.8/France:11.1/Germany:10.5/Italy:10.5/Spain:10.7. 
Humanistic burden (reported via physician ratings, on a scale of 1 (most impact) 
to 7 (least impact)) was (mean scores): patient ability to perform every-day tasks 
- 5EU:4.4/UK:4.4/France:5.1/Germany:3.8/Italy:4.5/Spain:4.0; patient ability to 
interact fully with family and friends - 5EU:4.9/UK:4.9/France:5.5/Germany:4.2/
Italy:5.0/Spain:4.9; patient ability to work/keep employment - 5EU:3.9/UK:4.2/
France:4.2/Germany:2.8/Italy:4.2/Spain:3.7. Percentage of patients hospitalized 
> = 1 in the past-year was 5EU:56%/UK:40%/France:68%/Germany:65%/Italy:65%/
Spain:57%. CONCLUSIONS: SLE patients experiencing flares had significant clini-
cal and humanistic burden across the studied countries. Further scrutiny is war-
ranted to assess the modalities of care delivered to this patient group to alleviate 
their burden.
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OBJECTIVES: Orphan drugs are indicated for rare diseases and conditions. We 
assessed trends in approvals of new drugs with orphan indications in the US 
and in the prevalence of orphan drugs approved by the FDA from 1983 to 2014 
compared to non-orphan drug approvals in the same time frame METHODS: The 
study used regulatory and prevalence data derived from the US FDA, the European 
Medicines Agency (EMA), and other publicly available sources. Descriptive statis-
tics and the chi-square test were performed in the study. RESULTS: A total of 103 
BLAs and 799 NMEs were approved by the FDA from 1983 to 2014. The percentage 
of new drugs with orphan designation at approval was 43.7% for BLAs and 20.7% 
for NMEs (p< 0.001). Orphan drugs represented 13.9% of the new drugs approved 
from 1983 to 1989, 21.2% in the 1990s, 25.5% in the 2000s, and 33.8% from 2010 to 
2014. Information about the prevalence of disease was available for 73.7% of the 
orphan drugs. Indications approved for use in diseases with a prevalence of less 
than 1000 patients (i.e.: ultra-orphan drugs) represented 8.4% of all new orphan 
drugs. Ultra-orphan drugs represented 12.5%, 3.6%, 7.7%, and 15.8% of all orphan 
indications approved in the US from 1983-1989, 1990s, 2000s, and 2010-2014, 
respectively. CONCLUSIONS: This study found an increase in the percentage of 
drugs approved by the FDA for orphan diseases and conditions. Ultra orphan drugs 
revealed a greater increase over time than other orphan drugs as a proportion of 
all new drugs approved by the FDA. The limited innovation in diseases with large 
prevalence, the incentives provided by the Orphan Drug Act of 1982 and favorable 
reimbursement for orphan drugs in the US health care system may explain the 
increase in the approval of orphan drugs in the US.
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pain or bleeding completed a pain history and five PRO instruments (EQ-5D-5L, 
Brief Pain Inventory v2 [BPI], SF-36v2, International Physical Activity Questionnaire 
[IPAQ], and Hemophilia Activities List [HAL]) during routine clinic visits. To assess 
concordance of individual questionnaire items and correlation of domain/global 
scores using intraclass correlation coefficient (ICC), initial patients (target 125-150) 
were approached to complete the PROs at the end of their 3-4 hour visit in a simi-
lar non-bleeding state. RESULTS: From October 2013-October 2014, 381 patients 
enrolled; 164 (88% of initial 187) completed the retest. Median age of retest cohort 
was 33.9 years (Q1, Q3; 26.9, 46.0). Median time for completion of the initial survey 
with five PROs was 36.0 minutes and for the retest was 21.0 minutes. Median/mean 
time between tests was 1.5/1.6 hours. The majority of subjects had hemophilia 
A (74.4%) and were white-non-Hispanic (72.6%); 48.7% were married, 62.6% had 
some college or graduate-level education, 80.7% were employed, and 61.0% were 
overweight or obese. HCV was more common than HIV (49.4% vs 16.5%); 61.0% 
self-reported arthritis/bone/joint problems. Median/mean test-retest concord-
ance was: EQ-5D-5L, 80.0%/79.1%; BPI, 54.5%/58.9%; SF-36v2, 77.8%/76.4%; IPAQ, 
100%/100%; and HAL, 77.4%/75.9%. ICC for test-retest reliability were: EQ-5D-5L 
Health Index, 0.890; BPI–severity, 0.950; BPI–interference, 0.920; IPAQ total activity, 
0.940; SF-36v2 overall health, 0.910; HAL total score, 0.970. CONCLUSIONS: All five 
PROs are reliable in adult PWH. Therefore, the choice of instrument to be used for 
research or clinical care should be driven by instrument characteristics other than 
reliability.
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OBJECTIVES: Patient reported outcomes provide important information on the 
comprehensive impact of Systemic Lupus Erythematosus (SLE) on daily lives of 
patients. It also fosters patient physician communication, patient engagement and 
satisfaction with medical care. LupusPRO is a disease targeted patient reported 
outcome tool that has good measurement properties (Jolly et al., 2012) and has 
been validated in several countries. Herein we report the measurement properties 
of the Italian translation of the LupusPRO that was administered using a web based 
format. METHODS: LupusPRO was translated using forwards and back translation 
method into Italian language. It was pretested among 5 native Italian speaking 
subjects. As part of another study, 344 patients with SLE diagnoses were approached 
through the Patients organization network, asked to provide their demographics, 
medications and responses to the online LupusPRO. We evaluated internal consist-
ency reliability (ICR) of the LupusPRO domain items, floor-ceiling effects, known 
groups validity (KGV) and confirmatory factor analysis (CFA). ICR was tested using 
cronbach’s α . KGV was tested against current use of corticosteroids, with the hypoth-
esis that SLE patients currently on corticosteroids would have worse health status 
than without. Goodness of fit was evaluated in the CFA. RESULTS: Mean (SD) age 
and duration of disease were 39.7 (11.1) and 11.7 (9.3) yrs. Ninety one percent were 
women. Sixty four percent were on corticosteroids and sixty six percent were on 
hydroxychloroquine at the time of the study. ICR and Floor-ceiling effects were 
acceptable. The hypothesis about corticosteroids was supported for many subscales. 
On CFA, with few exceptions the items correlated highly (r> 0.5) with their hypoth-
esized scale. The CFI was 0.938 and TLI was 0.973 (> 0.9 is considered good model 
fit). The RMSEA was 0.093 (< 0.1 is considered acceptable model fit). CONCLUSIONS: 
Web version of LupusPRO Italian translation shows fair psychometric properties in 
Systemic Lupus Erythematosus patients.
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OBJECTIVES: Allogeneic hematopoietic stem cell transplantation (HSCT) can 
cure Sickle Cell Disease (SCD) but traditional chemotherapy-based conditioning 
regimens for HSCT are associated with substantial morbidity and mortality. The 
objective of this study was to determine if an innovative approach of chemo-
therapy-free, non-myeloablative HSCT with alemtuzumab is associated with 
improved health-related quality of life (HRQoL) in adult SCD patients. METHODS: 
Thirteen high-risk SCD patients underwent chemotherapy-free HSCT at a large 
urban academic medical center using human leukocyte antigen (HLA)-matched, 
related donors. Indications for transplantation in this cohort included frequent 
pain crises, stroke, and/or ≥ 2 lifetime episodes of acute chest syndrome. Generic 
HRQoL was assessed using the SF-36 in 9 patients who were assessed pre-HSCT 
and at 365 post-HSCT. Magnitude of effect was evaluated for SF-36 norm-based 
subscales and the SF-6D summary scores based on standardized response mean 
(SRM) (SRM> 0.5= medium; SRM> 0.8= large effect). RESULTS: Of 13 patients, all 
survived and 9 had completed 365 day post-HSCT assessments by time of analy-
sis. Mean change scores 365-day post-HSCT were 4.6 (SD 21.3) for physical func-
tioning (PF) (SRMPF= 0.2), 9.0 (SD 23.0) for role physical (RP) (SRMRP= 0.4), 17.1 
(SD 14.2) for bodily pain (BP) (SRMBP= 1.20), 18.6 (SD 16.0) for general health (GH) 
(SRMGH= 1.16), 15.2 (SD 10.5) for vitality (VT) (SRMVT= 1.45), 13.0 (SD 17.2) for social 
function (SF) (SRMSF= 0.76), 5.1 (SD 14.7) for role emotional (RE) (SRMRE= 0.34), 
5.7 (SD 9.8) for mental health (MH) (SRMMH= 0.59) and 0.21 (SD 0.13) forSF-6D 
index score (SRMSF6D= 1.66). CONCLUSIONS: Our pilot study demonstrated a 
large magnitude of improvement in HRQoL in terms of BP, GH, VT and overall 
health according to the SF-6D for SCD patients undergoing chemotherapy-free, 
non-myeloablative HSCT with alemtuzumab. These promising results, which are 
the first report of the impact of this innovative treatment on HRQoL in adults, war-
rant further investigation with more patients under treatment and longer-term 
follow-up.
